Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events.

Klinger M, Zugmaier G, Nägele V, Goebeler ME, Brandl C, Stelljes M, Lassmann H, von Stackelberg A, Bargou RC, Kufer P.

Cancer Res. 2019 Oct 29. pii: canres.1131.2019. doi: 10.1158/0008-5472.CAN-19-1131. [Epub ahead of print]

PMID:
31662326
2.

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M.

Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514.

3.

Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Brozy J, Schlaepfer E, Mueller CKS, Rochat MA, Rampini SK, Myburgh R, Raum T, Kufer P, Baeuerle PA, Muenz M, Speck RF.

J Virol. 2018 Jun 29;92(14). pii: e00491-18. doi: 10.1128/JVI.00491-18. Print 2018 Jul 15.

4.

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.

Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A, Klinger M.

Exp Hematol Oncol. 2017 May 18;6:14. doi: 10.1186/s40164-017-0074-5. eCollection 2017.

5.

Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.

Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T, Baeuerle PA, Muenz M, Saelens X, Fiers W.

Antiviral Res. 2017 May;141:155-164. doi: 10.1016/j.antiviral.2017.02.016. Epub 2017 Mar 1.

PMID:
28257797
6.

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.

Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12. No abstract available.

7.

A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non-Small Cell Lung Cancer.

Mecklenburg I, Sienel W, Schmid S, Passlick B, Kufer P.

Clin Cancer Res. 2017 Mar 1;23(5):1213-1219. doi: 10.1158/1078-0432.CCR-16-0557. Epub 2016 Aug 19.

8.

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC.

J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.

PMID:
26884582
9.

Dual energy can accurately differentiate uric acid-containing urinary calculi from calcium stones.

Spek A, Strittmatter F, Graser A, Kufer P, Stief C, Staehler M.

World J Urol. 2016 Sep;34(9):1297-302. doi: 10.1007/s00345-015-1756-4. Epub 2016 Jan 9.

PMID:
26749082
10.

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.

Deisting W, Raum T, Kufer P, Baeuerle PA, Münz M.

PLoS One. 2015 Oct 28;10(10):e0141669. doi: 10.1371/journal.pone.0141669. eCollection 2015.

11.

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4.

PMID:
26239198
12.

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.

Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B.

Mol Cancer Ther. 2014 Jun;13(6):1549-57. doi: 10.1158/1535-7163.MCT-13-0956. Epub 2014 Mar 27.

13.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.

PMID:
24300852
14.

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW.

Leukemia. 2013 Apr;27(5):1107-15. doi: 10.1038/leu.2012.341. Epub 2012 Nov 26.

PMID:
23178753
15.

Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.

Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P.

Mol Cancer Ther. 2012 Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5.

16.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Köhne-Volland R, Brüggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou RC.

Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.

PMID:
23024237
17.

Blinatumomab: a historical perspective.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R.

Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Review.

PMID:
22940266
18.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P.

Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.

PMID:
22592608
19.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

PMID:
21576633
20.

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T.

Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44.

21.

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, Münz M.

PLoS One. 2010 Oct 18;5(10):e13474. doi: 10.1371/journal.pone.0013474.

22.

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.

Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12605-10. doi: 10.1073/pnas.1000976107. Epub 2010 Jun 28.

23.

Antibody recognition of a unique tumor-specific glycopeptide antigen.

Brooks CL, Schietinger A, Borisova SN, Kufer P, Okon M, Hirama T, Mackenzie CR, Wang LX, Schreiber H, Evans SV.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10056-61. doi: 10.1073/pnas.0915176107. Epub 2010 May 17.

24.

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.

Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P.

Cancer Immunol Immunother. 2010 Aug;59(8):1197-209. doi: 10.1007/s00262-010-0844-y. Epub 2010 Mar 23.

PMID:
20309546
25.

Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells.

Steigerwald J, Raum T, Pflanz S, Cierpka R, Mangold S, Rau D, Hoffmann P, Kvesic M, Zube C, Linnerbauer S, Lumsden J, Sriskandarajah M, Kufer P, Baeuerle PA, Volkland J.

MAbs. 2009 Mar-Apr;1(2):115-27. Epub 2009 Mar 11.

26.

Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.

Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum T, Münz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M.

J Immunother. 2009 Jun;32(5):452-64. doi: 10.1097/CJI.0b013e3181a1c097.

PMID:
19609237
27.

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G.

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Review.

PMID:
19455460
28.

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.

J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70.

PMID:
19342971
29.

BiTE: Teaching antibodies to engage T-cells for cancer therapy.

Baeuerle PA, Kufer P, Bargou R.

Curr Opin Mol Ther. 2009 Feb;11(1):22-30. Review.

PMID:
19169956
30.

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, Kufer P, Baeuerle PA.

Immunobiology. 2009;214(6):441-53. doi: 10.1016/j.imbio.2008.11.014. Epub 2009 Jan 20.

PMID:
19157637
31.

Induction of a T helper cell response against the tumor-associated antigen HER2 using monocyte-derived dendritic cells.

Metzger J, Nicklisch N, Kufer P, Peschel C, Luppa PB, Bernhard H.

Cytotechnology. 2002 Jan;38(1-3):155-64. doi: 10.1023/A:1021103723325.

32.

Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.

d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC.

Leuk Res. 2009 Mar;33(3):465-73. doi: 10.1016/j.leukres.2008.08.025. Epub 2008 Oct 2.

PMID:
18835037
33.

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P.

Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.

34.

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.

Amann M, Friedrich M, Lutterbuese P, Vieser E, Lorenczewski G, Petersen L, Brischwein K, Kufer P, Kischel R, Baeuerle PA, Schlereth B.

Cancer Immunol Immunother. 2009 Jan;58(1):95-109. doi: 10.1007/s00262-008-0529-y. Epub 2008 Jul 2.

PMID:
18594818
35.

Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, Krinner E, Bruckmeier S, Lippold S, Kischel R, Lutterbuese R, Kufer P, Baeuerle PA, Schlereth B.

Cancer Res. 2008 Jan 1;68(1):143-51. doi: 10.1158/0008-5472.CAN-07-2182.

36.

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.

Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, Schlereth B, Baeuerle PA.

J Immunother. 2007 Nov-Dec;30(8):798-807.

PMID:
18049331
37.

A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.

Mecklenburg I, Weckermann D, Zippelius A, Schoberth A, Petersen S, Prang N, Riethmüller G, Kufer P.

J Immunol Methods. 2007 Jun 30;323(2):180-93. Epub 2007 May 15.

PMID:
17540401
38.

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.

Cancer Res. 2007 Apr 15;67(8):3927-35.

39.

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.

Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, Prang N, Bargou R, Suzich J, Baeuerle PA, Hofmeister R.

Cancer Immunol Immunother. 2007 Oct;56(10):1551-63. Epub 2007 Feb 20.

PMID:
17310380
40.

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA.

Mol Immunol. 2007 Mar;44(8):1935-43. Epub 2006 Nov 2.

PMID:
17083975
41.
42.

A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.

Krinner EM, Hepp J, Hoffmann P, Bruckmaier S, Petersen L, Petsch S, Parr L, Schuster I, Mangold S, Lorenczewski G, Lutterbüse P, Buziol S, Hochheim I, Volkland J, Mølhøj M, Sriskandarajah M, Strasser M, Itin C, Wolf A, Basu A, Yang K, Filpula D, Sørensen P, Kufer P, Baeuerle P, Raum T.

Protein Eng Des Sel. 2006 Oct;19(10):461-70. Epub 2006 Jul 25.

PMID:
16868004
43.
44.

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.

Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA.

Mol Immunol. 2006 Feb;43(6):763-71. Epub 2005 Apr 26.

PMID:
16360021
45.

Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1 infection.

Mack M, Pfirstinger J, Haas J, Nelson PJ, Kufer P, Riethmüller G, Schlöndorff D.

J Immunol. 2005 Dec 1;175(11):7586-93.

46.

BiTEs: bispecific antibody constructs with unique anti-tumor activity.

Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA.

Drug Discov Today. 2005 Sep 15;10(18):1237-44. Review.

PMID:
16213416
47.

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.

Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, da Silva A, Locher M, Kischel R, Lutterbüse R, Kufer P, Baeuerle PA.

Cancer Immunol Immunother. 2006 Jul;55(7):785-96. Epub 2005 Sep 27.

PMID:
16187083
48.

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.

Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.

Mol Immunol. 2006 Mar;43(8):1129-43. Epub 2005 Sep 1.

PMID:
16139892
49.

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.

Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA.

Cancer Immunol Immunother. 2006 May;55(5):503-14. Epub 2005 Jul 20.

PMID:
16032400
50.

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.

Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R, Baeuerle PA.

Cancer Res. 2005 Apr 1;65(7):2882-9.

Supplemental Content

Support Center